Table 1 Table showing list of established Patient-Derived Tumour Organoids (PDTOs)

Digestive

Pancreatic Cancer

62% (52/83)

[34]

75% (103/138)

[35]

85% (17/20)

[36]

[20]

Colorectal Cancer

100%

[37]

~ 90% (22/27)

[38]

Hepatocellular Carcinoma

26% (10/38)

[39]

100% (13/17)

[40]

Gastric Carcinoma

50%

[41]

71% (10/14)

[42]

Metastatic Gastrointestinal Carcinoma

70% (> 100)

[43]

76% (13/17)

[44]

Esophageal Carcinoma

31% (10/32)

[45]

Appendiceal Carcinoma

75% (9/12)

[46]

Respiratory

Lung Carcinoma

88% (n = 16)

[47]

Non-Small Cell Lung Cancer

71.43% (10/14)

[48]

(Primary & Metastatic)

100% (3/3)

[49]

28% (n = 18)

[47]

Mesothelioma

100% (2/2)

[50]

Urinary

Prostate Cancer

(Primary & Metastatic)

16% (4/25)

[51]

18% (6/32)

[52]

Bladder Carcinoma

70% (12/17)

[53]

Renal Cell Carcinoma

74% (25/35)

[54]

Reproductive

Breast carcinoma

~ 80% (> 155)

[30]

Endometrial Carcinoma

100% (15/15)

[29]

Ovarian Cancer

65% (n = 32)

[55]

Nervous

Glioblastoma

91.4% overall

[56]

66.7% (IDH1 mutant)

75% (recurrent)